Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Sodium-glucose cotransporter-2 inhibition exacerbates hepatic encephalopathy in biliary cirrhotic rats.

Authors:
Shao-Jung Hsu Hui-Chun Huang Chon Kit Pun Ching-Chih Chang Chiao-Lin Chuang Yi-Hsiang Huang Ming-Chih Hou Fa-Yauh Lee

J Pharmacol Exp Ther 2022 Aug 4. Epub 2022 Aug 4.

Taipei Veterans General Hospital, Taiwan.

In liver cirrhosis, hepatic inflammation and abundant portal-systemic collaterals are indicated for the development of hepatic encephalopathy. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a type of anti-diabetic agent, which exert pleiotropic and anti-inflammatory effects. Diabetes and chronic liver disease often coexist but the influence of SGLT-2 inhibition on liver cirrhosis and hepatic encephalopathy remains unknown. This study investigated the effect of SGLT-2 inhibition on cirrhotic rats. Biliary cirrhosis was induced in Sprague-Dawley rats via common bile duct ligation. A total of 2-weeks treatment with the SGLT-2 inhibitor, empagliflozin 30 mg/kg/day, was applied. The motor activities, hemodynamics, biochemistry parameters, plasma levels of vascular endothelial growth factor (VEGF) and the severity of portal-systemic collateral shunts were measured. The hepatic histopathology and protein expressions were examined. We found that empagliflozin treatment did not affect hemodynamics, liver biochemistry or blood glucose levels in cirrhotic rats. Empagliflozin did not affect hepatic inflammation and fibrosis. The protein expression of factors related to liver injury were not influenced by empagliflozin. However, empagliflozin decreased motor activities in cirrhotic rats and increased portal-systemic collateral shunts and VEGF plasma levels. In summary, SGLT-2 inhibition by empagliflozin did not ameliorate portal hypertension and hepatic inflammation in cirrhotic rats. In contrast, it exacerbated hepatic encephalopathy, which was evidenced by a decrease in motor activity. A possible mechanism could be an increase of portal-systemic shunts related to VEGF up-regulation. Therefore, empagliflozin use should be cautious in cirrhotic patients regarding the development of hepatic encephalopathy. Sodium-glucose cotransporter-2 inhibition by empagliflozin did not ameliorate portal hypertension and hepatic inflammation of cirrhotic rats. In contrast, it exacerbated hepatic encephalopathy through increased portal-systemic shunts related to VEGF up-regulation.

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.122.001289DOI Listing
August 2022

Publication Analysis

Top Keywords

cirrhotic rats
24
hepatic encephalopathy
24
hepatic inflammation
16
sodium-glucose cotransporter-2
12
sglt-2 inhibition
12
shunts vegf
12
hepatic
11
collateral shunts
8
motor activities
8
portal-systemic collateral
8
ameliorate portal
8
inflammation cirrhotic
8
vegf up-regulation
8
portal hypertension
8
portal-systemic shunts
8
plasma levels
8
development hepatic
8
encephalopathy sodium-glucose
8
inhibition empagliflozin
8
empagliflozin
8

Keyword Occurance

Similar Publications

Sodium-glucose cotransporter-2 inhibition exacerbates hepatic encephalopathy in biliary cirrhotic rats.

Authors:
Shao-Jung Hsu Hui-Chun Huang Chon Kit Pun Ching-Chih Chang Chiao-Lin Chuang Yi-Hsiang Huang Ming-Chih Hou Fa-Yauh Lee

J Pharmacol Exp Ther 2022 Aug 4. Epub 2022 Aug 4.

Taipei Veterans General Hospital, Taiwan.

In liver cirrhosis, hepatic inflammation and abundant portal-systemic collaterals are indicated for the development of hepatic encephalopathy. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a type of anti-diabetic agent, which exert pleiotropic and anti-inflammatory effects. Diabetes and chronic liver disease often coexist but the influence of SGLT-2 inhibition on liver cirrhosis and hepatic encephalopathy remains unknown. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Silymarin Administration Attenuates Cirrhotic-induced Cardiac Abnormality in the Rats: A Possible Role of β-adrenergic Receptors and L-type Voltage-Dependent Calcium Channels.

Authors:
Gholamreza Bayat Roham Mazloom Seyed Ali Hashemi Khalil Pourkhalili Parviz Fallah Alireza Shams Parvaneh Esmaeili Azadeh Khalili

Iran J Med Sci 2022 Jul;47(4):367-378

Department of Physiology-Pharmacology-Medical Physics, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.

Background: Cirrhotic cardiomyopathy is a well-recognized cardiac dysfunction in cirrhotic patients. Studies have confirmed the protective effects of silymarin in different types of cardiac injury. This study aimed to examine the effectiveness and molecular mechanism of silymarin against myocardial dysfunction and hypertrophy in a rat model of cirrhosis. Read More

View Article and Full-Text PDF
July 2022
Similar Publications

Extracellular Vesicles From Hyperammonemic Rats Induce Neuroinflammation in Cerebellum of Normal Rats: Role of Increased TNFα Content.

Authors:
Paula Izquierdo-Altarejos Mar Martínez-García Vicente Felipo

Front Immunol 2022 13;13:921947. Epub 2022 Jul 13.

Laboratory of Neurobiology, Príncipe Felipe Research Centre, Valencia, Spain.

Hyperammonemia plays a main role in the neurological impairment in cirrhotic patients with hepatic encephalopathy. Rats with chronic hyperammonemia reproduce the motor incoordination of patients with minimal hepatic encephalopathy, which is due to enhanced GABAergic neurotransmission in cerebellum as a consequence of neuroinflammation. Extracellular vesicles (EVs) could play a key role in the transmission of peripheral alterations to the brain to induce neuroinflammation and neurological impairment in hyperammonemia and hepatic encephalopathy. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Hyperammonaemia induces mitochondrial dysfunction and neuronal cell death.

Authors:
Plamena R Angelova Annarein J C Kerbert Abeba Habtesion Andrew Hall Andrey Y Abramov Rajiv Jalan

JHEP Rep 2022 Aug 23;4(8):100510. Epub 2022 May 23.

Institute for Liver and Digestive Health, University College London, Royal Free Campus, London, UK.

Background & Aims: In cirrhosis, astrocytic swelling is believed to be the principal mechanism of ammonia neurotoxicity leading to hepatic encephalopathy (HE). The role of neuronal dysfunction in HE is not clear. We aimed to explore the impact of hyperammonaemia on mitochondrial function in primary co-cultures of neurons and astrocytes and in acute brain slices of cirrhotic rats using live cell imaging. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Effects of PCSK-9 Inhibition by Alirocumab Treatments on Biliary Cirrhotic Rats.

Authors:
Hui-Chun Huang Shao-Jung Hsu Ching-Chih Chang Chiao-Lin Chuang Ming-Chih Hou Fa-Yauh Lee

Int J Mol Sci 2022 Jul 2;23(13). Epub 2022 Jul 2.

Faculty of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.

Hyperlipidemia and oxidative stress with elevated oxidized low-density lipoprotein (ox-LDL) exacerbate hepatic inflammation and fibrosis. The plasma level of low-density lipoprotein (LDL) is controlled by proprotein convertase subtilisin/kexin 9 (PCSK9). Alirocumab is a monoclonal antibody that decreases LDL via inhibiting PCSK9 function. Read More

View Article and Full-Text PDF
July 2022
Similar Publications
}
© 2022 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap